Hasan Karanlik1, Neslihan Cabioglu2, Adela Luciana Oprea3, Ilker Ozgur2, Naziye Ak4, Adnan Aydiner4, Semen Onder5, Süleyman Bademler1, Bahadir M Gulluoglu6. 1. Surgical Oncology Unit, Institute of Oncology, Istanbul University, Istanbul, Turkey. 2. Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 3. Department of Gynecology, Targu Mures University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania. 4. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. 5. Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6. Breast and Endocrine Surgery Unit, Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey.
Abstract
BACKGROUND AND OBJECTIVES: Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer treated up-front with systemic treatment. Both breast-conserving surgery and sentinel lymph node biopsy (SLNB) are controversial issues in the management of IBC. In this study, we aimed to assess the feasibility of SLNB in pathologically proven node-positive IBC patients. METHODS: All patients with a histopathological diagnosis of IBC and biopsy-proven metastatic axillary lymph nodes underwent systemic treatment. Patients with a complete clinical response in the axilla who underwent SLNB followed by standard axillary dissection were analyzed. RESULTS: The study consisted of 25 female patients. The identification rate (IR) and the false negativity rate (FNR) were 17/25 and 2/10, respectively. Overall, 9/25 and 7/25 of patients had a complete pathological response (pCR) in the breast and axilla after systemic treatment, respectively. Although the pCR in the axilla was 2/4 in nonluminal HER2-positive patients, the highest IR 4/4 and the lowest FNR 0/2 were determined in these patients. In triple-negative patients, however, the IR was 2/4 and the FNR was found to be 0/2. CONCLUSIONS: SLNB may be considered in selected axilla-downstaged IBC patients including patients with a pCR with HER2-positive and triple-negative tumors. Axillary dissection may be, therefore, omitted in those with negative SLNs.
BACKGROUND AND OBJECTIVES: Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer treated up-front with systemic treatment. Both breast-conserving surgery and sentinel lymph node biopsy (SLNB) are controversial issues in the management of IBC. In this study, we aimed to assess the feasibility of SLNB in pathologically proven node-positive IBC patients. METHODS: All patients with a histopathological diagnosis of IBC and biopsy-proven metastatic axillary lymph nodes underwent systemic treatment. Patients with a complete clinical response in the axilla who underwent SLNB followed by standard axillary dissection were analyzed. RESULTS: The study consisted of 25 female patients. The identification rate (IR) and the false negativity rate (FNR) were 17/25 and 2/10, respectively. Overall, 9/25 and 7/25 of patients had a complete pathological response (pCR) in the breast and axilla after systemic treatment, respectively. Although the pCR in the axilla was 2/4 in nonluminal HER2-positive patients, the highest IR 4/4 and the lowest FNR 0/2 were determined in these patients. In triple-negative patients, however, the IR was 2/4 and the FNR was found to be 0/2. CONCLUSIONS: SLNB may be considered in selected axilla-downstaged IBC patients including patients with a pCR with HER2-positive and triple-negative tumors. Axillary dissection may be, therefore, omitted in those with negative SLNs.
Keywords:
HER2-positive breast cancer; Inflammatory breast cancer; Neoadjuvant systemic treatment; Sentinel lymph node biopsy; Triple-negative breast cancer
Authors: Sarah M DeSnyder; Elizabeth A Mittendorf; Carissa Le-Petross; Savitri Krishnamurthy; Gary J Whitman; Naoto T Ueno; Wendy A Woodward; Henry M Kuerer; Catherine L Akay; Gildy V Babiera; Wei Yang; Anthony Lucci Journal: Clin Breast Cancer Date: 2017-07-10 Impact factor: 3.225
Authors: G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Vered Stearns; C Alexander Ewing; Rebecca Slack; Marie F Penannen; Daniel F Hayes; Theodore N Tsangaris Journal: Ann Surg Oncol Date: 2002-04 Impact factor: 5.344
Authors: S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli Journal: Ann Oncol Date: 2010-07-05 Impact factor: 32.976
Authors: Arjun Menta; Tamer M Fouad; Anthony Lucci; Huong Le-Petross; Michael C Stauder; Wendy A Woodward; Naoto T Ueno; Bora Lim Journal: Surg Clin North Am Date: 2018-05-24 Impact factor: 2.741
Authors: Kelly J Rosso; Audree B Tadros; Anna Weiss; Carla L Warneke; Sarah DeSnyder; Henry Kuerer; Naoto T Ueno; Shane R Stecklein; Wendy A Woodward; Anthony Lucci Journal: Ann Surg Oncol Date: 2017-08-01 Impact factor: 5.344